LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
March 04, 2024 at 07:30 am EST
Share
LENSAR, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 6.45 million compared to USD 5.92 million a year ago. Revenue was USD 42.16 million compared to USD 35.36 million a year ago.
Net loss was USD 14.38 million compared to USD 19.91 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 1.96 a year ago. Diluted loss per share from continuing operations was USD 1.31 compared to USD 1.96 a year ago.
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR, INC. 
